Fosigotifator is under clinical development by Calico Life Sciences and currently in Phase II for Unspecified Central Nervous System Disorders.
Google’s ( GOOGL) anti-aging company Calico released disappointing trial results of its first ever drug.
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Calico, Google's anti-aging subsidiary, has announced disappointing results from its first-ever drug trial. The experimental ...
The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...
A clinical trial evaluating the drug fosigotifator in patients with amyotrophic lateral sclerosis has failed to meet its primary endpoint, according to topline results from the Healey ALS platform ...
Calico's drug, called fosigotifator, is one of a handful run through a clinical trial platform at Massachusetts General Hospital, which disclosed fosigotifator's topline study results Monday.
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Medpage Today on MSN3d
Herpes and Alzheimer's Tau; Dementia and Autism; Extended Paxlovid for Long COVIDA study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...
DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback